Nuo Therapeutics CEO exercises options, gets new grant

Nuo Therapeutics CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 on June 30, 2026 through a net exercise that delivered 1,608 common shares after 160,892 shares were withheld at $1.01 for exercise price and taxes.

Rhea-AI Filing Summary

Nuo Therapeutics CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 on June 30, 2026 through a net exercise that delivered 1,608 common shares after 160,892 shares were withheld at $1.01 for exercise price and taxes. He also received a grant of 125,000 options at $1.01 on June 29, 2026, expiring June 29, 2036, with one third exercisable as of June 30, 2027 and the balance vesting quarterly over the following two years. Following these updates and a 25,381-share correction from a prior report, he directly holds 2,061,227 common shares and 125,000 options.

Insider Trade Summary

162,500 shares exercised/converted

Exercise 4 txns

Insider JORDEN DAVID EMERSON

Role CEO/CFO

Type	Security	Shares	Price	Value
Exercise	Option to purchase common stock	162,500	$0.00	$0.00
Exercise	Common Stock	162,500	$1.00	$163K
Exercise Price or Tax Liability	Common Stock	160,892	$1.01	$163K
Grant/Award	Option to purchase common stock	125,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 125,000 contracts (Direct); Common Stock — 2,061,227 shares (Direct)

Footnotes (4)

1. F1. Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.
2. F2. Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4.
3. F3. 62,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017.
4. F4. One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

Key Figures

Options exercised: 162,500 shares Shares withheld for taxes: 160,892 shares Net shares received: 1,608 shares +4 more

7 metrics

Options exercised 162,500 shares Options to purchase common stock exercised on June 30, 2026 at $1.00 per share

Shares withheld for taxes 160,892 shares Common shares withheld on June 30, 2026 using the closing price of $1.01

Net shares received 1,608 shares Common shares received from the net exercise of 162,500 stock options

New options granted 125,000 options Options granted June 29, 2026 with a $1.01 exercise price, expiring June 29, 2036

Common stock holdings 2,061,227 shares Direct common stock beneficially owned after the reported transactions

Option holdings 125,000 options Direct options to purchase common stock outstanding after the grant and exercise

Beneficial ownership adjustment 25,381 shares Correction to prior Form 4 beneficial ownership from June 5, 2026

Key Terms

net exercise, beneficially owned, closing price, vest quarterly

4 terms

net exercise financial

"Represents a net exercise of outstanding stock options."

A net exercise is a way to convert stock options into shares without paying cash up front: instead of handing over money to buy the optioned shares, the holder receives only the number of shares equal to the option’s value after the company withholds a portion of shares to cover the exercise price and taxes. It matters to investors because it changes how many new shares are issued, affects dilution of existing shareholders, and alters company cash flow compared with a cash exercise.

beneficially owned financial

"to correct the amount of securities beneficially owned as a result of the transaction"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

closing price financial

"for payment of the exercise price using the closing price of $1.01"

vest quarterly financial

"One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nuo Therapeutics (AURX) report for its CEO?

Nuo Therapeutics reported that CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 per share using a net exercise, had 160,892 shares withheld to cover costs, received 1,608 common shares, and was granted a new 125,000-option award in June 2026.

How many options did the Nuo Therapeutics (AURX) CEO exercise and what were the tax withholdings?

He exercised 162,500 stock options at $1.00 per share, with the issuer withholding 160,892 common shares at a closing price of $1.01 to satisfy the exercise price and tax obligations, resulting in 1,608 net shares of common stock delivered.

What are the terms of the new stock option grant at Nuo Therapeutics (AURX)?

On June 29, 2026, the CEO received a 125,000-option grant with a $1.01 exercise price, expiring June 29, 2036. One third of these options are exercisable as of June 30, 2027, with the remaining options vesting quarterly over the subsequent two years.

How many Nuo Therapeutics (AURX) shares and options does the CEO hold after these transactions?

After the reported activity and a share-count correction, the CEO directly holds 2,061,227 shares of common stock and 125,000 options to purchase common stock, reflecting both the June 2026 net option exercise and the new option grant’s addition to his holdings.

What was the 25,381-share adjustment mentioned in the Nuo Therapeutics (AURX) Form 4?

The filing notes a 25,381-share adjustment to correct the previously reported amount of securities beneficially owned from a Form 4 filed on June 5, 2026, aligning the CEO’s disclosed ownership with the actual impact of that earlier transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 09:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JORDEN DAVID EMERSON

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO/CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		M		162,500	A	$1	2,222,119(2)	D
Common Stock	06/30/2026		F(1)		160,892	D	$1.01	2,061,227(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$1	06/30/2026		M			162,500	12/31/2017(3)	06/30/2026	Common Stock	162,500	$0	0	D
Option to purchase common stock	$1.01	06/29/2026		A		125,000		(4)	06/29/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

2. Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4.

3. 62,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017.

4. One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

	/s/ David Jorden	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)